Certara, Inc. (NASDAQ:CERT) Q4 2022 Results Conference Call March 1, 2023 5:00 PM ET

Company Participants

David Deuchler - Investor Relations

William Feehery - Chief Executive Officer

Andrew Schemick - Chief Financial Officer

Conference Call Participants

David Windley - Jefferies

Vikram Purohit - Morgan Stanley

Luke Sergott - Barclays

Dan Leonard - Credit Suisse

Joy Zhang - SVB Securities

Operator

Good day, and thank you for standing by. Welcome to the Certara Fourth Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers presentation, there will be a question-and-answer session [Operator Instructions]. Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, David Deuchler, Investor Relations. Please go ahead.

David Deuchler

Good afternoon, everyone. Thank you all for participating in today's conference call. On the call from Certara, we have William Feehery, Chief Executive Officer; and Andrew Schemick, Chief Financial Officer.

Earlier today, Certara released financial results for the ended December 31, 2022. A copy of the press release is available on the company's Web site. Before we begin, I'd like to remind you that management will make statements during this call that will include forward-looking statements and actual results may differ materially from those expressed or implied in the forward-looking statements. Please refer to Slide 2 in the accompanying materials for additional information, which you can find on the company's Investor Relations site. In our remarks or responses to questions, management may mention some non-GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures are available in the recent earnings release available on the company's Web site. For additional information, please refer to the reconciliation tables in the accompanying materials. This conference call contains time sensitive information and is accurate only as of the live broadcast today, March 01, 2023. Certara disclaims any obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise.

And with that, I'll turn the call over to William.

William Feehery

Thank you, David. Good afternoon, everyone. And thank you for joining Certara's fourth quarter and full year earnings call. Andrew and I will start with prepared remarks and then we will take questions. We are pleased with the strong finish to 2022 and we have made significant progress across our key initiatives throughout the year. We believe we are well positioned for 2023 and beyond as we execute Certara's mission to disrupt drug innovation with our proprietary biosimulation technology and services. At Certara, we are focused on safely accelerating the drug development process by lowering the cost and increasing the probability of success in trials to improve the health and well being of millions of people globally. Before we get into the details of the quarter, I would like to announce the appointment of John Gallagher as Certara's new CFO effective April 1st. John is a proven finance executive with experience as a public company CFO at Cue Health and a prior career in senior finance roles at Beckman Dickinson, GE and Ford. After eight successful years as CFO of Certara, Andrew Schemick, has decided that this is a good time for him to pursue other career goals. And I'm very pleased that he will be staying with Certara in a key operational and strategic role after helping with the transition to John.